| AR and DCAF6 |
androgen receptor |
DDB1 and CUL4 associated factor 6 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
| AR and HDAC4 |
androgen receptor |
histone deacetylase 4 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Signaling by NOTCH
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- NOTCH1 Intracellular Domain Regulates Transcription
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
| AR and TCF4 |
androgen receptor |
transcription factor 4 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- CDO in myogenesis
- Myogenesis
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
| AR and NFKB1 |
androgen receptor |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Signaling by the B Cell Receptor (BCR)
- NF-kB is activated and signals survival
- Downstream TCR signaling
- Toll Like Receptor 7/8 (TLR7/8) Cascade
- Cellular Senescence
- RIP-mediated NFkB activation via ZBP1
- Toll Like Receptor TLR6:TLR2 Cascade
- DEx/H-box helicases activate type I IFN and inflammatory cytokines production
- Activated TLR4 signalling
- Toll Like Receptor TLR1:TLR2 Cascade
- Downstream signaling events of B Cell Receptor (BCR)
- FCERI mediated NF-kB activation
- MyD88 cascade initiated on plasma membrane
- Toll Like Receptor 5 (TLR5) Cascade
- ZBP1(DAI) mediated induction of type I IFNs
- p75NTR signals via NF-kB
- Transcriptional regulation of white adipocyte differentiation
- MyD88 dependent cascade initiated on endosome
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- MyD88:Mal cascade initiated on plasma membrane
- Toll Like Receptor 9 (TLR9) Cascade
- Innate Immune System
- Regulated proteolysis of p75NTR
- Signalling by NGF
- TRIF-mediated TLR3/TLR4 signaling
- Cytosolic sensors of pathogen-associated DNA
- Senescence-Associated Secretory Phenotype (SASP)
- Cytokine Signaling in Immune system
- p75 NTR receptor-mediated signalling
- MyD88-independent cascade
- Toll Like Receptor 2 (TLR2) Cascade
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- Signaling by Interleukins
- TCR signaling
- Toll-Like Receptors Cascades
- Toll Like Receptor 10 (TLR10) Cascade
- Interleukin-1 processing
- Toll Like Receptor 3 (TLR3) Cascade
- Toll Like Receptor 4 (TLR4) Cascade
- Activation of NF-kappaB in B cells
- Fc epsilon receptor (FCERI) signaling
- TRAF6 mediated NF-kB activation
- Interleukin-1 signaling
- Adaptive Immune System
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
- Thalidomide
- Pranlukast
- Triflusal
|
|
|
| AR and ZMIZ1 |
androgen receptor |
zinc finger, MIZ-type containing 1 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
| AR and SMARCA2 |
androgen receptor |
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 |
- Generic Transcription Pathway
- Nuclear Receptor transcription pathway
|
- Chromatin modifying enzymes
- Chromatin organization
- RMTs methylate histone arginines
|
- Levonorgestrel
- Spironolactone
- Flutamide
- Oxandrolone
- Testosterone
- Nilutamide
- Fludrocortisone
- Drostanolone
- Nandrolone phenpropionate
- Bicalutamide
- Fluoxymesterone
- Drospirenone
- Danazol
- Testosterone Propionate
- Delta1-dihydrotestosterone
- Boldenone
- Calusterone
- Flufenamic Acid
- Dihydrotestosterone
- (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
- Methyltrienolone
- (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
- Cyproterone
- Methyltestosterone
- 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
- (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
- 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
- (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
- 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
- (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
- (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
- (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
- S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
- 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
- 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
- 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
- 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
- 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
- Nandrolone decanoate
- Enzalutamide
|
|
|
|
| ARNTL and KAT2B |
aryl hydrocarbon receptor nuclear translocator-like |
K(lysine) acetyltransferase 2B |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- RNA Polymerase I Transcription Initiation
- RNA Polymerase I Promoter Clearance
- HATs acetylate histones
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Generic Transcription Pathway
- Pre-NOTCH Transcription and Translation
- Signaling by NOTCH1
- Pre-NOTCH Expression and Processing
- Signaling by NOTCH1 in Cancer
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- Chromatin organization
- RNA Polymerase I Transcription
- Signaling by NOTCH
- Notch-HLH transcription pathway
- NOTCH1 Intracellular Domain Regulates Transcription
- Chromatin modifying enzymes
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
|
|
|
|
| ARNTL and HIF1A |
aryl hydrocarbon receptor nuclear translocator-like |
hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Cellular response to hypoxia
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
- Signaling by NOTCH
- Regulation of gene expression by Hypoxia-inducible Factor
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- NOTCH1 Intracellular Domain Regulates Transcription
- Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha
- Signaling by NOTCH1
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Signaling by NOTCH1 in Cancer
- FBXW7 Mutants and NOTCH1 in Cancer
|
|
|
|
|
| ARNTL and RARA |
aryl hydrocarbon receptor nuclear translocator-like |
retinoic acid receptor, alpha |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- Generic Transcription Pathway
- Signaling by Retinoic Acid
- Nuclear Receptor transcription pathway
- Orphan transporters
|
|
- Adapalene
- Acitretin
- Alitretinoin
- Tazarotene
- Etretinate
- Isotretinoin
- Tamibarotene
|
|
|
| ARNTL and PER3 |
aryl hydrocarbon receptor nuclear translocator-like |
period circadian clock 3 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
|
|
|
|
|
| ARNTL and UBE2I |
aryl hydrocarbon receptor nuclear translocator-like |
ubiquitin-conjugating enzyme E2I |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- Post-translational protein modification
- SUMOylation
- Meiotic synapsis
- Processing and activation of SUMO
- SUMO is transferred from E1 to E2 (UBE2I, UBC9)
|
|
|
|
|
| ARNTL and EPAS1 |
aryl hydrocarbon receptor nuclear translocator-like |
endothelial PAS domain protein 1 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- Cellular response to hypoxia
- Transcriptional regulation of pluripotent stem cells
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
- Oxygen-dependent asparagine hydroxylation of Hypoxia-inducible Factor Alpha
- Regulation of gene expression by Hypoxia-inducible Factor
|
|
|
|
|
| ARNTL and CSNK1E |
aryl hydrocarbon receptor nuclear translocator-like |
casein kinase 1, epsilon |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- Organelle biogenesis and maintenance
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- G2/M Transition
- Assembly of the primary cilium
- Signaling by Wnt
- Regulation of PLK1 Activity at G2/M Transition
- Anchoring of the basal body to the plasma membrane
- Cell Cycle, Mitotic
- WNT mediated activation of DVL
- Loss of proteins required for interphase microtubule organization from the centrosome
- TCF dependent signaling in response to WNT
- RNF mutants show enhanced WNT signaling and proliferation
- Loss of Nlp from mitotic centrosomes
- XAV939 inhibits tankyrase, stabilizing AXIN
- Centrosome maturation
- Signaling by WNT in cancer
- Mitotic G2-G2/M phases
- Recruitment of mitotic centrosome proteins and complexes
|
|
|
|
|
| ARNTL and HLF |
aryl hydrocarbon receptor nuclear translocator-like |
hepatic leukemia factor |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
|
|
|
|
|
| ARNTL and SUMO3 |
aryl hydrocarbon receptor nuclear translocator-like |
small ubiquitin-like modifier 3 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- SUMO is proteolytically processed
- Post-translational protein modification
- SUMOylation
- SUMO is conjugated to E1 (UBA2:SAE1)
- SUMO is transferred from E1 to E2 (UBE2I, UBC9)
- Processing and activation of SUMO
|
|
|
|
|
| ARNTL and SUMO2 |
aryl hydrocarbon receptor nuclear translocator-like |
small ubiquitin-like modifier 2 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- SUMO is proteolytically processed
- Post-translational protein modification
- SUMOylation
- SUMO is conjugated to E1 (UBA2:SAE1)
- SUMO is transferred from E1 to E2 (UBE2I, UBC9)
- Processing and activation of SUMO
|
|
|
|
|
| ARNTL and CLOCK |
aryl hydrocarbon receptor nuclear translocator-like |
clock circadian regulator |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- PPARA activates gene expression
- Chromatin modifying enzymes
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Chromatin organization
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- HATs acetylate histones
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
|
|
|
|
| ARNTL and BHLHE40 |
aryl hydrocarbon receptor nuclear translocator-like |
basic helix-loop-helix family, member e40 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
|
|
|
|
| ARNTL and RXRA |
aryl hydrocarbon receptor nuclear translocator-like |
retinoid X receptor, alpha |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- Bile acid and bile salt metabolism
- Metabolism of lipids and lipoproteins
- Nuclear Receptor transcription pathway
- Metabolic disorders of biological oxidation enzymes
- Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
- Generic Transcription Pathway
- Endogenous sterols
- Synthesis of bile acids and bile salts
- Orphan transporters
- Defective FMO3 causes Trimethylaminuria (TMAU)
- Signaling by Retinoic Acid
- Recycling of bile acids and salts
- Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
- Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
- Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
- Regulation of pyruvate dehydrogenase (PDH) complex
- Pyruvate metabolism
- Synthesis of bile acids and bile salts via 27-hydroxycholesterol
- Defective MAOA causes Brunner syndrome (BRUNS)
- Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
- Activation of gene expression by SREBF (SREBP)
- The citric acid (TCA) cycle and respiratory electron transport
- Transcriptional activation of mitochondrial biogenesis
- PPARA activates gene expression
- Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
- Organelle biogenesis and maintenance
- Import of palmitoyl-CoA into the mitochondrial matrix
- Pyruvate metabolism and Citric Acid (TCA) cycle
- Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
- Phase 1 - Functionalization of compounds
- RORA activates circadian gene expression
- Regulation of cholesterol biosynthesis by SREBP (SREBF)
- Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
- Cytochrome P450 - arranged by substrate type
- Transcriptional regulation of white adipocyte differentiation
- Biological oxidations
- Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
- Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
- Fatty acid, triacylglycerol, and ketone body metabolism
- Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
- Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
- REV-ERBA represses gene expression
- Defective CYP1B1 causes Glaucoma
- Mitochondrial biogenesis
- Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
- Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
- Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
- Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol
- Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
- YAP1- and WWTR1 (TAZ)-stimulated gene expression
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
|
- Adapalene
- Bexarotene
- Acitretin
- Alitretinoin
- Etodolac
- Etretinate
- (5BETA)-PREGNANE-3,20-DIONE
- 2-chloro-5-nitro-N-phenylbenzamide
- 1-BENZYL-3-(4-METHOXYPHENYLAMINO)-4-PHENYLPYRROLE-2,5-DIONE
- 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
- tributylstannanyl
|
|
|
| ARNTL and EP300 |
aryl hydrocarbon receptor nuclear translocator-like |
E1A binding protein p300 |
- PPARA activates gene expression
- Fatty acid, triacylglycerol, and ketone body metabolism
- Metabolism of lipids and lipoproteins
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- REV-ERBA represses gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- RORA activates circadian gene expression
|
- Signaling by NOTCH1 HD Domain Mutants in Cancer
- Metabolism of lipids and lipoproteins
- Signaling by Wnt
- NOTCH2 intracellular domain regulates transcription
- Regulation of gene expression by Hypoxia-inducible Factor
- Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
- Signaling by NOTCH2
- Pre-NOTCH Transcription and Translation
- RNF mutants show enhanced WNT signaling and proliferation
- Signaling by NOTCH1 in Cancer
- Chromatin organization
- misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
- Signaling by NOTCH
- formation of the beta-catenin:TCF transactivating complex
- Factors involved in megakaryocyte development and platelet production
- Chromatin modifying enzymes
- LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
- Signaling by NOTCH1 PEST Domain Mutants in Cancer
- Mitotic G2-G2/M phases
- Constitutive Signaling by NOTCH1 PEST Domain Mutants
- PPARA activates gene expression
- Cellular response to hypoxia
- Regulation of Hypoxia-inducible Factor (HIF) by oxygen
- Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
- Attenuation phase
- G2/M Transition
- HATs acetylate histones
- RORA activates circadian gene expression
- HSF1-dependent transactivation
- TRAF3-dependent IRF activation pathway
- Signaling by NOTCH1
- Transcriptional regulation of white adipocyte differentiation
- XAV939 inhibits tankyrase, stabilizing AXIN
- Pre-NOTCH Expression and Processing
- Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
- FBXW7 Mutants and NOTCH1 in Cancer
- Innate Immune System
- Fatty acid, triacylglycerol, and ketone body metabolism
- Cytosolic sensors of pathogen-associated DNA
- Cellular response to heat stress
- REV-ERBA represses gene expression
- Cell Cycle, Mitotic
- RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
- NOTCH1 Intracellular Domain Regulates Transcription
- TCF dependent signaling in response to WNT
- TRAF6 mediated IRF7 activation
- Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
- Signaling by WNT in cancer
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- Polo-like kinase mediated events
|
|
|
|
|